INTRODUCTION
============

Overactive bladder (OAB) is a symptom-driven condition characterized by urinary urgency with or without urgency urinary incontinence and is usually associated with increased daytime frequency and nocturia \[[@B1]\]. Several epidemiologic studies in Europe, Canada, the United States, and Japan have shown OAB syndrome to be present in 8.0% to 16.5% of adults, with similar rates between men and women \[[@B2][@B3][@B4][@B5]\]. A population-based survey conducted in Korea demonstrated that the overall prevalence of OAB is 12.2% in the general population over the age of 18 years (10.0% of men and 14.3% of women) \[[@B6]\]. The prevalences of OAB as reported in several population-based studies are briefly summarized in [Table 1](#T1){ref-type="table"}.

OAB is a heterogeneous condition with a multifactorial underlying pathophysiology that is not yet completely understood \[[@B7]\]. OAB is responsible for a considerable disease burden in terms of detrimental effects on quality of life and high socioeconomic burden. Patients with OAB have more urinary tract infections, skin infections, and sleep disturbances and are at greater risk of falls and fractures \[[@B8][@B9]\]. OAB symptoms are associated with serious negative effects on activities of daily living and emotional well-being, work productivity, and social relationships \[[@B10][@B11]\]. Patients with OAB tend to have low self-esteem and to isolate themselves. Moreover, the symptom of urge incontinence increases the risks of hospitalization and admission to a nursing home and may contribute to depression \[[@B4][@B12][@B13]\]. Therefore, the goal of OAB management is to reduce the occurrence and severity of OAB symptoms to improve quality of life.

The treatment of OAB is usually started with behavioral therapies \[[@B14]\]. If behavioral therapies are not effective or are only partially effective, oral pharmacotherapy, such as muscarinic receptor antagonists (antimuscarinics) and β3-adrenoceptor agonists, can be offered as a second-line therapy. Because of the chronic nature of OAB, long-term use of OAB medication is related to positive health outcomes and a decrease in health care resource use. As with many chronic conditions that require long-term medication, good persistence and compliance with OAB medication is essential for pharmacotherapy to be beneficial. Thus, patients\' persistence and compliance during the course of pharmacotherapy is a major issue in the treatment of OAB. The following review presents what is known about drug persistence and compliance in OAB and the factors influencing medication-taking in OAB.

TERMINOLOGY OF MEDICATION PERSISTENCE AND COMPLIANCE
====================================================

The concepts of drug persistence and compliance are multidimensional. The terms *persistence*, *compliance*, and *adherence* are used across different therapeutic areas and have been defined in various ways. Thus, there is immense confusion over the use of the terms related to this subject. Because of this lack of uniformity in the definitions of the concepts of drug persistence and compliance, health care providers and researchers needed standard and useful definitions. To address these issues, the International Society for Pharmacoeconomics and Outcomes Research Medication Compliance and Persistence Work Group developed definitions for drug persistence and compliance \[[@B15]\]. Although conceptually similar, medication persistence and compliance are two different constructs. *Medication persistence* refers to the duration of drug therapy, whereas *medication compliance* refers to the intensity of drug use during the duration of therapy.

Medication persistence is generally used to refer the act of continuing the treatment for the prescribed duration without exceeding a permissible gap \[[@B15]\]. Persistence can also be defined as the overall duration of time from initiation to discontinuation of therapy. By definition, persistence is commonly reported as a dichotomous variable as being \"persistent\" or \"nonpersistent.\" It can also be reported as a continuous variable, such as the number of days for which therapy was available. On the other hand, the discontinuation rate refers to the proportion of patients who stop taking a treatment.

Medication compliance refers to the act of conforming to the recommendations about day-to-day treatment as prescribed in terms of timing, dosage, and frequency of medication-taking \[[@B15]\]. It may be defined as the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen. Compliance is measured as administered doses per defined period of time and is commonly reported as a percentage. Many different methods are used to assess compliance with medications. Although there is no standardized method, the medication possession ratio is a common measure. The medication possession ratio is calculated as the sum of the days with a supply of any prescribed drug divided by the total days followed up, with at least 80% often indicating good compliance \[[@B16][@B17]\]. Adherence is a synonym of compliance. The term *adherence* emphasizes the importance of the role of the patient in defining and actively engaging in their treatments to decide whether to adhere to the prescriber\'s recommendation rather than passively following the prescriber\'s orders \[[@B18]\]. However, there is no reliable evidence for the assumption that adherence is a superior term or is preferred by patients, and there is also a concern that adherence seems too sticky a concept \[[@B15][@B19]\]. Therefore, compliance continues to be the more popular term.

Regardless of which term is preferred, it is obvious that the maximal benefit of the available medication will be achieved if patients follow the prescriber\'s recommendation appropriately and closely. As noted above, persistence and compliance are the preferred terms and we will thus use them here to avoid further confusion.

IMPORTANCE OF PERSISTENCE AND COMPLIANCE WITH MEDICATION IN THE TREATMENT OF OAB
================================================================================

Several studies clearly demonstrate an increasing incidence of OAB over time as well as a persistence of symptoms that illustrates the chronic nature of this disease. The severity of OAB symptoms progresses dynamically over long time periods, such as the progression in OAB symptoms from OAB dry to OAB wet \[[@B20][@B21][@B22]\]. Moreover, there is no authoritative evidence that pharmacological therapy can correct the underlying pathophysiology of OAB. Thus, OAB may require long-term treatment to achieve reliable control of symptoms \[[@B23]\]. Actually, Rogers et al. \[[@B24]\] reported that patients who received tolterodine for 6 months showed continuous improvement in voiding diary parameters compared with those who received the medication for only 3 months.

In most cases, OAB symptoms relapse after discontinuation of pharmacotherapy. Discontinuation of OAB treatment often results in retreatment. For example, Choo et al. \[[@B25]\] reported that discontinuation of OAB medication after successful treatment for 12 weeks led to the recurrence of OAB symptoms in many patients. In their study, most patients showed recurring frequency and urgency that became bothersome, as evidenced by the high retreatment rate and the decreasing satisfaction rate at 16 weeks. According to Lee et al. \[[@B26]\], discontinuation of tolterodine after successful treatment led to a recurrence of OAB symptoms in 67% of patients, resulting in a high retreatment rate of 65% within 3 months, irrespective of treatment periods.

Recently, Kim et al. \[[@B27]\] reported that good persistence of OAB medication was associated with greater symptom improvement and increased quality of life. Improvements in scores on the OAB symptom questionnaire and the OABquestionnaire short form were significantly greater in patients who were persistent with antimuscarinics than in those who were nonpersistent with antimuscarinics. This means that patients who were persistent with OAB medication experienced fewer symptoms from OAB and had a higher quality of life during their pharmacotherapy.

In chronic conditions requiring long-term and consistent pharmacotherapy, medication persistence and compliance are critical predictors of treatment outcomes. Furthermore, patients with poor persistence and compliance with pharmacotherapy are at a higher risk for morbidity and mortality and for increased health care costs compared with patients with good persistence and compliance \[[@B28]\]. Like other chronic diseases, OAB typically requires good persistence and compliance with pharmacotherapy \[[@B29]\].

PERSISTENCE AND COMPLIANCE AMONG PATIENTS RECEIVING PHARMACOLOGICAL THERAPY FOR OAB
===================================================================================

Currently, oral pharmacotherapy is a mainstay of OAB treatment. The two major classes of oral pharmacotherapy for treating the symptoms of OAB are antimuscarinics and β3-adrenoceptor agonists. Among them, the principal drugs used for relieving OAB symptoms are antimuscarinics. Numerous antimuscarinics are currently available that are highly effective for patients of all ages with OAB \[[@B7]\].

Persistence of drug therapy is typically low in many chronic diseases \[[@B30]\], but the persistence seen with antimuscarinics in OAB appears to be markedly poorer than for other types of chronic medications, such as statins, osteoporosis drugs, antidiabetic drugs, and antihypertensive drugs. Medication persistence and compliance are diverse with respect to type of antimuscarinics, formulations and dosing, study designs, and study duration. All of these factors may affect rates of persistence and compliance, and trends reported must be interpreted within the context of these variables.

Several randomized double-blind clinical trials have demonstrated that 6% to 31% of OAB patients prematurely discontinued their antimuscarinics after 12 weeks of therapy \[[@B31][@B32][@B33][@B34][@B35][@B36][@B37][@B38][@B39][@B40]\]. Generally, there was a tendency toward an increase in discontinuation rates during the longer follow-up periods. According to the type of antimuscarinics, rates of discontinuation for 12 weeks were 7% to 19% of those taking tolterodine, 13% to 31% of those taking oxybutynin, 6% to 9% of those taking solifenacin, and 14% to 20% of those taking fesoterodine. In randomized open-label or openlabel extension studies, the rates of discontinuation were somewhat higher and showed higher rates with longer follow-up periods. In these studies, overall discontinuation rates were 10% to 67% of those taking antimuscarinics with various follow-up durations \[[@B41][@B42][@B43][@B44]\].

In retrospective medical claims studies, rates of discontinuation are markedly higher than what has been reported in clinical trials. In a systematic review of medical claims studies, persistence began to fall off within the first prescription period, and rates of discontinuation of antimuscarinics were 43% to 83% within the first 30 days \[[@B16][@B17][@B45][@B46]\]. Based on claims from a Medicaid population from California, Yu et al. \[[@B16]\] found that 88.6% of patients with chronic OAB discontinued their pharmacotherapy after a median of 50 days during a 12-month study. Shaya et al. \[[@B47]\] also found that the 12-month persistence rates were 5% to 9% in Medicaid patients prescribed antimuscarinics. A similar pattern was noted for persistence in treatment-naïve patients. In a retrospective cohort study of those aged 66 years and above who were newly prescribed either oxybutynin or tolterodine conducted in Canada \[[@B48]\], persistence on oxybutynin and tolterodine was 18.9% and 27.3% at 12 months, respectively. After 2 years of followup, persistence was 9.4% and 16.9% for oxybutynin and tolterodine, respectively. In a retrospective study based on real prescription data from the United Kingdom \[[@B49]\], 65% to 86% of patients discontinued their initial antimuscarinics at 12 months regardless of types of antimuscarinics.

Several studies have described persistence of antimuscarinics on the basis of real clinical practice. Medication persistence in real clinical practice may be substantially different from that in clinical trials. Persistence to treatments is often better in clinical trials than it is in real clinical practice. In a clinical trial setting, patients may be more motivated and cooperative with their prescribed recommendations than they are otherwise. On the other hand, studies conducted in real clinical practice have high external validity and allow greater generalization than clinical trials. In one study, Dmochowski and Newman \[[@B50]\] reported that approximately 53% had been taking their medication for 1 year or longer in a self-administered survey of volunteers to serve in an online research panel, and just 32% of participants were completely satisfied with their current medications. In a postal-based survey conducted in the United States, 24.5% of patients who had been prescribed antimuscarinics for OAB reported that they had discontinued one or more antimuscarinic prescription medications during the previous 12 months \[[@B29]\]. In other open-label observational studies, the rates of medication discontinuation in 12 months were 21% to 78% of those taking antimuscarinics \[[@B27][@B51][@B52][@B53][@B54]\]. In a multicenter, prospective, and observational study conducted in Korea \[[@B27]\], 56.8% of patients with OAB remained on their antimuscarinics at 24 weeks. The persistence at 4 and 12 weeks was 85.6% and 71.4%, respectively. Among those who were persistent to their antimuscarinics, compliance with the medication was 75.6%, 53.8%, and 34.3% after 4, 12, and 24 weeks, respectively. Lee et al. \[[@B53]\] reported that only 25% of men with benign prostatic obstruction and OAB remained on their solifenacin add-on therapy after tamsulosin monotherapy within one year in a real clinical environment. Kim et al. \[[@B54]\] also reported that 1-year persistence on solifenacin was 22.1% in a prospective, multicenter, observational study conducted in Korea. In their study, persistence at 12, 24, and 36 weeks was 72.4%, 45.8%, and 31.1%, respectively. In addition, the compliance among patients who were persistent to their solifenacin treatment was 94.1% at 1 year. [Fig. 1](#F1){ref-type="fig"} shows the trend of persistence of antimuscarinics in three observational studies conducted in Korea.

Although antimuscarinics are the cornerstone pharmacotherapy for OAB, they usually give rise to anticholinergic adverse events, such as dry mouth and constipation, which may be one of the major factors leading to poor persistence with these medications. More recently, the introduction of mirabegron, the first commercially available β3-adrenoceptor agonist for the treatment of OAB, has widened the therapeutic options for the management of OAB \[[@B55]\]. Mirabegron is well known to have a mechanism of action and side-effect profile different from that of antimuscarinics. In a systematic review including numerous randomized controlled trials, mirabegron was as efficacious as antimuscarinics in reducing the storage symptoms of OAB, but had a side-effect profile similar to that of placebo \[[@B56]\]. In a retrospective analysis conducted at a single center based on real clinical practice, persistence with mirabegron for OAB at 3 months was 69% and fell to 48% by 6 months \[[@B57]\]. In a retrospective medical claims study from a Canadian database \[[@B58]\], persistence in OAB patients prescribed either mirabegron or other antimuscarinics was compared over 12 months. Patients who were prescribed mirabegron remained on their pharmacotherapy longer than did those who received antimuscarinics. The median numbers of days on mirabegron in the treatment-naïve cohort and treatment-experienced cohort were 196 and 299 days, respectively. A similar pattern was observed in patients who were prescribed the different antimuscarinics. The median numbers of days in the treatment-naïve and treatmentexperienced cohort were 70 to 100 days and 96 to 242 days, respectively. In the treatment-naïve cohort, persistence at 12 months was 29.9% with mirabegron, compared with 13.8% to 21.0% with antimuscarinics. Furthermore, patients taking mirabegron demonstrated significantly higher compliance than did those taking antimuscarinics (64.5% for mirabegron vs. 18.6% to 49.2% for the various antimuscarinics). Individual studies that evaluated the medication-taking status of oral pharmacotherapy for OAB are briefly summarized in [Table 2](#T2){ref-type="table"}.

IMPROVING PERSISTENCE WITH PHARMACOLOGICAL TREATMENT FOR OAB
============================================================

The reasons underlying the low rates of persistence for OAB pharmacotherapy in clinical practice are diverse. Personal, clinical, and environmental factors can influence patients\' persistence and compliance with OAB pharmacotherapy, regardless of causes. It seems likely that discontinuation is affected by many factors, including adverse events, unmet expectations of treatment, and recognition by patients of the chronic nature of their symptoms \[[@B58]\]. Sometimes, many patients discontinue their OAB pharmacotherapy before the full therapeutic effects have been established. Persistence rates vary between antimuscarinics; although this may be partly linked to differences in efficacy and tolerability, persistence is generally better with extended-release and once-daily formulations \[[@B16][@B47][@B59]\]. In the study by Shaya et al. \[[@B47]\], only 32% of patients taking an oxybutynin immediate-release formulation persisted with the medication after 30 days. On the other hand, 44% of patients taking either long-acting tolterodine extended-release and oxybutynin extendedrelease persisted with the medication for longer than 30 days. Several studies have found that older patients are more likely than younger patients to persist in taking OAB pharmacotherapy \[[@B27][@B47][@B49][@B54][@B58]\]. Female sex also can be a risk factor for discontinuation of OAB pharmacotherapy \[[@B54][@B58]\].

A survey conducted in the United State in 2005 examined reasons for discontinuing OAB pharmacotherapy \[[@B60]\]. In this survey, the most important considerations in discontinuing medication for most patients were ef fectiveness and side ef fects. The most commonly reported reason for discontinuing treatment was unmet treatment expectations (46.2%). Many patients (21.1%) were discontinuing OAB medication primarily because of side effects. These findings suggest that clinicians should be familiar with identifying and managing patients\' unmet expectations. In addition, assessing goal achievement for the most bothersome symptoms might be able to enhance persistence and compliance by promoting realistic expectations about treatment efficacy and side effects. A support program may also improve persistence and compliance for OAB pharmacotherapy by providing patients with educational materials about the nature of OAB and advice about the importance of taking their medication as recommended. Klutke et al. \[[@B61]\] suggests that the addition of focused, written behavioral intervention to antimuscarinics might enhance improvements in OAB symptoms and treatment satisfaction in those who are dissatisfied with antimuscarinics. Wyman et al. \[[@B62]\] also suggest behavioral intervention and lifestyle modification, which can be used as an adjunct therapy to enhance pharmacotherapy for OAB.

CONCLUSIONS
===========

The successful treatment of OAB is mainly related to medication persistence and compliance, which is affected by several factors, such as inadequate efficacy and bothersome side effects. In general, persistence and compliance with antimuscarinic medication for OAB are poor. Although the available studies are limited, mirabegron is somewhat associated with higher levels of persistence with OAB treatment than the antimuscarinics. For optimal outcomes of OAB pharmacotherapy, improved persistence is an important goal in the treatment of OAB. Improving persistence and compliance with OAB pharmacotherapy is a challenge for both patients and clinicians. Assessing the individualized needs of each patient and goal achievement for the most bothersome symptoms as well as patient support programs can be good strategies to improve persistence and compliance with OAB pharmacotherapy. What we need today are efforts to find more effective and promising strategies for improving persistence and compliance with OAB pharmacotherapy. This would go along with addressing patients\' expectations and effectively managing OAB symptoms and improving patients\' quality of life.
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###### The prevalence of overactive bladder in conducted population-based studies
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  Variable                Korea \[[@B6]\]    Finland \[[@B2]\]   Europe and Canada \[[@B3]\]   United States \[[@B4]\]   Japan \[[@B5]\]
  ----------------------- ------------------ ------------------- ----------------------------- ------------------------- -----------------
  No. of respondents      2,000              3,727               19,165                        5,204                     4,570
  Response rate (%)       22.1               62.4                33.0                          44.3                      45.3
  Age distribution (y)    ≥18                18-79               ≥18                           ≥18                       40-100
  Survey method           Telephone survey   Postal survey       Telephone survey              Telephone survey          Postal survey
  Prevalence of OAB (%)                                                                                                  
   Men                    10.0               6.5                 10.8                          16.0                      14.0
   Women                  14.3               9.3                 12.8                          16.9                      11.0
   Overall                12.2               8.0                 11.8                          16.5                      12.4

###### Summary of studies on the medication-taking status of overactive bladder patients

![](icu-57-84-i002)

  Study                                    Study design                              Drug                        No.                   Outcome measurement                Length of follow-up   Results
  ---------------------------------------- ----------------------------------------- --------------------------- --------------------- ---------------------------------- --------------------- ------------------------------------------
  Abrams et al. \[[@B31]\]                 Randomized controlled study               Tolterodine                 150                   Discontinuation rate               12 Weeks              11.3%
  Rogers et al. \[[@B32]\]                 Randomized controlled study               Tolterodine                 201                   Discontinuation rate               12 Weeks              18.9%
  Cardozo et al. \[[@B33]\]                Randomized controlled study               Solifenacin                 576                   Discontinuation rate               12 Weeks              7.6%
  Nitti et al. \[[@B34]\]                  Randomized controlled study               Fesoterodine                562                   Discontinuation rate               12 Weeks              20.3%
  Drutz et al. \[[@B35]\]                  Randomized controlled study               Tolterodine                 Tolterodine: 109      Discontinuation rate               12 Weeks              Tolterodine: 12.8%
  Oxybutynin                               Oxybutynin: 112                           Oxybutynin: 31.3%                                                                                          
  Homma et al. \[[@B36]\]                  Randomized controlled study               Tolterodine                 Tolterodine: 240      Discontinuation rate               12 Weeks              Tolterodine: 10.4%
  Oxybutynin                               Oxybutynin: 246                           Oxybutynin: 23.2%                                                                                          
  Armstrong et al. \[[@B37]\]              Randomized controlled study               Tolterodine                 Tolterodine: 399      Discontinuation rate               12 Weeks              Tolterodine: 10.5%
  Oxybutynin                               Oxybutynin: 391                           Oxybutynin: 13.3%                                                                                          
  Chapple et al. \[[@B38]\]                Randomized controlled study               Tolterodine                 Tolterodine: 263      Discontinuation rate               12 Weeks              Tolterodine: 9.9%
  Solifenacin                              Solifenacin: 547                          Solifenacin: 8.6%                                                                                          
  Chapple et al. \[[@B39]\]                Randomized controlled study               Tolterodine                 Tolterodine: 599      Discontinuation rate               12 Weeks              Tolterodine: 7.3%
  Solifenacin                              Solifenacin: 578                          Solifenacin: 5.9%                                                                                          
  Chapple et al. \[[@B40]\]                Randomized controlled study               Tolterodine                 Tolterodine: 290      Discontinuation rate               12 Weeks              Tolterodine: 12.8%
  Fesoterodine                             Fesoterodine: 559                         Fesoterodine: 13.8%                                                                                        
  Giannitsas et al. \[[@B41]\]             Randomized open-label study               Tolterodine                 128                   Discontinuation rate               6 Weeks               16.4%
  Oxybutynin                                                                                                                                                                                    
  Sand et al. \[[@B42]\]                   Randomized open-label study               Tolterodine                 Tolterodine: 163      Discontinuation rate               12 Weeks              Tolterodine: 10.4%
  Oxybutynin                               Oxybutynin: 152                           Oxybutynin: 14.5%                                                                                          
  Salvatore et al. \[[@B43]\]              Randomized open-label study               Oxybutynin                  66                    Discontinuation rate               2 Years               66.7%
  Abrams et al. \[[@B44]\]                 Open-label extension study                Tolterodine                 714                   Discontinuation rate               52 Weeks              38.2%
  Yu et al. \[[@B16]\]                     Retrospective medical claims study        OAB medication              2,415                 Discontinuation rate               52 Weeks              Discontinuation rate: 88.6%
  Compliance rate                          Compliance rate : 0.7%                                                                                                                               
  Shaya et al. \[[@B47]\]                  Retrospective medical claims study        Tolterodine or oxybutynin   1,637                 Persistence rate                   52 Weeks              Tolterodine ER: 9%
  Oxybutynin ER: 6%; Oxybutynin IR: 5%                                                                                                                                                          
  Gomes et al. \[[@B48]\]                  Retrospective medical claims study        Tolterodine                 Tolterodine: 24,855   Persistence rate                   52 Weeks              Tolterodine: 27.3%
  Oxybutynin                               Oxybutynin: 31,996                        Oxybutynin: 18.9%                                                                                          
  2 Years                                  Tolterodine: 13.6%                                                                                                                                   
  Oxybutynin: 9.4%                                                                                                                                                                              
  Wagg et al. \[[@B58]\]                   Retrospective medical claims study        Mirabegron                  1,683                 Persistence rate                   52 Weeks              Persistence rate: 31.7%
  Compliance rate                          Compliance rate: 64.5%                                                                                                                               
  Wagg et al. \[[@B49]\]                   Retrospective study                       Tolterodine                 4,833                 Persistence rate                   12 Weeks              Tolterodine ER: 47%; Tolterodine IR: 46%
  Solifenacin                              Solifenacin: 58%                                                                                                                                     
  Oxybutynin                               Oxybutynin ER: 44%; Oxybutynin IR: 40%                                                                                                               
  Propiverine                              Propiverine: 47%                                                                                                                                     
  Trospium                                 Trospium: 42%                                                                                                                                        
  Darifenacin                              Darifenacin: 52%                                                                                                                                     
  Flavoxate                                Flavoxate: 28%                                                                                                                                       
  24 Weeks                                 Tolterodine ER: 36% Tolterodine IR: 33%                                                                                                              
  Solifenacin: 46%                                                                                                                                                                              
  Oxybutynin ER: 35%; Oxybutynin IR: 29%                                                                                                                                                        
  Propiverine: 36%                                                                                                                                                                              
  Trospium: 33%                                                                                                                                                                                 
  Darifenacin: 30%                                                                                                                                                                              
  Flavoxate: 16%                                                                                                                                                                                
  52 Weeks                                 Tolterodine ER: 28% Tolterodine IR: 24%                                                                                                              
  Solifenacin: 35%                                                                                                                                                                              
  Oxybutynin ER: 26%; Oxybutynin IR: 22%                                                                                                                                                        
  Propiverine: 27%                                                                                                                                                                              
  Trospium: 26%                                                                                                                                                                                 
  Darifenacin: 17%                                                                                                                                                                              
  Flavoxate: 14%                                                                                                                                                                                
  Pindoria et al. \[[@B57]\]               Retrospective study                       Mirabegron                  197                   Persistence rate                   12 Weeks              69%
  24 Weeks                                 48%                                                                                                                                                  
  Diokno et al. \[[@B51]\]                 Open-label study                          Oxybutynin                  1,067                 Discontinuation rate               52 Weeks              53.8%
  Homma et al. \[[@B52]\]                  Open-label study                          Imidafenacin                478                   Discontinuation rate               52 Weeks              21.3%
  Lee et al. \[[@B53]\]                    Prospective, observational study          Solifenacin                 176                   Persistence rate                   12 Weeks              56.8%
  24 Weeks                                 40.9%                                                                                                                                                
  52 Weeks                                 25.0%                                                                                                                                                
  Kim et al. \[[@B27]\]                    Prospective, observational study          Any antimuscarinics         952                   Persistence rate Compliance rate   4 Weeks               Persistence rate: 85.6%
  Compliance rate: 75.6%                                                                                                                                                                        
  12 Weeks                                 Persistence rate: 71.4%                                                                                                                              
  Compliance rate: 53.8%                                                                                                                                                                        
  24 Weeks                                 Persistence rate: 56.8%                                                                                                                              
  Compliance rate: 34.3%                                                                                                                                                                        
  Kim et al. \[[@B54]\]                    Prospective, observational study          Solifenacin                 1018                  Persistence rate                   12 Weeks              Persistence rate: 72.4%
  Compliance rate                                                                                                                                                                               
  24 Weeks                                 Persistence rate: 45.8%                                                                                                                              
  36 Weeks                                 Persistence rate: 31.1%                                                                                                                              
  52 Weeks                                 Persistence rate: 22.1%                                                                                                                              
  Compliance rate: 94.1%                                                                                                                                                                        

OAB, overactive bladder; ER, extended-release; IR, immediate-release.
